Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Deferred Revenue: 2011-2025

Historic Current Deferred Revenue for Niagen Bioscience (NAGE) over the last 10 years, with Sep 2025 value amounting to $292,000.

  • Niagen Bioscience's Current Deferred Revenue rose 58.70% to $292,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $292,000, marking a year-over-year increase of 58.70%. This contributed to the annual value of $611,000 for FY2024, which is 213.33% up from last year.
  • Niagen Bioscience's Current Deferred Revenue amounted to $292,000 in Q3 2025, which was down 3.63% from $303,000 recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Current Deferred Revenue peaked at $611,000 during Q4 2024, and registered a low of $141,000 during Q1 2022.
  • Its 3-year average for Current Deferred Revenue is $243,455, with a median of $195,000 in 2023.
  • As far as peak fluctuations go, Niagen Bioscience's Current Deferred Revenue tumbled by 42.09% in 2021, and later soared by 213.33% in 2024.
  • Niagen Bioscience's Current Deferred Revenue (Quarterly) stood at $161,000 in 2021, then dropped by 2.48% to $157,000 in 2022, then increased by 24.20% to $195,000 in 2023, then surged by 213.33% to $611,000 in 2024, then soared by 58.70% to $292,000 in 2025.
  • Its last three reported values are $292,000 in Q3 2025, $303,000 for Q2 2025, and $207,000 during Q1 2025.